SEC EDGARAUG 122 min read$REPL

Patel Sushil sold $510K of REPL

Patel Sushil (Chief Executive Officer) sold 39,341 shares of Replimune Group, Inc. (REPL) at $12.97 ($0.51M total) on 2026-08-10.

Original reporting

SEC EDGAR · Patel Sushil

Published Aug 12, 2026, 9:07 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 12, 2026, 9:14 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$REPL

Neutral

medium confidence

Mentioned

$REPL

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$REPLNeutralLow

Why it matters

Traders may treat the CEO sale as a mild negative sentiment input, but without additional company news it is unlikely to drive a sustained repricing.

Market read

A newly filed insider sale provides incremental sentiment information for REPL, but no fundamental catalyst is disclosed.

What to watch

The article does not state whether the sale was part of compensation, tax planning, or other non-informational motives, and it provides no 10b5-1 plan details.

Relevance 5/10Novelty 5/10Timing: Form 4 filed 2026-08-12, covering sale dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for Replimune Group, Inc.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$REPLNeutralMedium confidence

Context

Replimune CEO Patel Sushil sold 39,341 shares on 2026-08-10 for about $510,252, per a newly filed Form 4.

Expected impact

Near-term impact likely limited, with any effect more sentiment-driven than fundamental.

Evidence & confidence

The filing is primary-source and time-stamped, but it is an open-market sale with no 10b5-1 plan disclosed and no accompanying company-specific operational or guidance change.

Market effects

Sector

No sector-wide implication is provided; this is company-specific insider trading disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be routine liquidity management and may not signal reduced confidence, especially without any stated linkage to company events.

Key entities

issuer
Replimune Group, Inc.
US-listed company whose CEO filed an insider sale on Form 4.
insider
Patel Sushil
Chief Executive Officer and officer/director who sold shares.

Read at source ← All news

SEP 11

$MRNAHighAI 9/10

New FDA Drug Approvals - August 2026

The FDA approved 13 drugs in August 2026, including Moderna's mFLUSIVA ($149.56/dose) for influenza prevention, Takeda's Orezyful for narcolepsy, Replimune's Tudriqev ($450,000/course) for melanoma, Bristol-Myers Squibb's Zenbexus ($29,500/28-day cycle) for multiple myeloma, Lantheus' Tauklarify for Alzheimer's diagnosis, and Regeneron's Pasatru for FOP. Each drug showed positive clinical trial results.

finanznachrichten.de3 min

SEP 11

$REPLHighAI 8/10

REPL Stock Tracks Best Day Ever: This Analyst Sees Higher Approval Odds For Replimune’s Melanoma After ‘Overwhelmingly Positive’ Panel Outcome

Replimune Group (REPL) stock surged 140% in pre-market trading after a favorable FDA advisory committee review of its melanoma therapy RP1. Cantor Fitzgerald upgraded REPL to 'Overweight' from 'Neutral', citing an 'overwhelmingly positive' panel outcome. The FDA is expected to make a final decision by Aug. 2, 2026. REPL's stock has fallen 39% year-to-date.

stocktwits.com2 min

SEP 4

$REPLMed

Did FDA’s RP1 Rejection and New Lawsuits Just Shift Replimune Group’s (REPL) Risk Narrative?

Replimune Group (REPL) faces securities class action lawsuits following the FDA's rejection of its RP1 Biologics License Application due to study design issues. The company will discuss its outlook at the Cantor Global Healthcare Conference. Analysts note increased regulatory and legal risks, with shares potentially trading above fair value.

simplywall.st2 min

SEP 3

$REPLHighAI 9/10

FDA Leadership Overrules Staff Concerns To Grant Replimune Accelerated Approval For Tudriqev

Replimune (REPL) received FDA accelerated approval for its cancer therapy Tudriqev, despite staff concerns, after senior FDA leadership intervened. The Oncology Center of Excellence played a key role. Accelerated approval requires confirmatory trials. This marks a significant milestone for Replimune in the competitive oncology market.

londoninsider.co.uk2 min

SEP 2

$REPLHighAI 8/10

Replimune Group stock hits 52-week high at 16.2 USD

Replimune Group Inc (REPL) hit a 52-week high of $16.20, up 165.99% over the past year. Analysts have mixed views, with price targets ranging from $14 to $24. The FDA's approval of its cancer treatment, TUDRIQEV, has drawn positive attention from analysts, with upgrades and increased price targets. The company's earnings report is anticipated to impact stock movement.

investing.com2 min

AUG 27

$REPLLowAI 8/10

ReplimuneÂ Group Lawsuit: Company Asks Court to Dismiss Securities Case Over RP1 FDA Approval Process - TipRanks.com

Replimune Group (NASDAQ: REPL) and its leaders filed a motion to dismiss a lawsuit alleging securities violations over statements about its melanoma treatment RP1's FDA approval process. The investors claim Replimune misled them about FDA feedback on the IGNYTE trial. Replimune argues it disclosed risks and that the FDA ultimately approved RP1 in August 2026.

tipranks.com2 min